This opportunity uses the R01 Research Project Grant Program (Clinical Trial Optional) funding mechanism.
The purpose of this Funding Opportunity Announcement (FOA) is to identify abnormalities in circadian-ordered gene expression to improve our understanding of disease phenotypes, etiology, risk stratification, resilience, and therapeutic management in diseases.
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Submission Requirements & Due Date
- 30 August 2019 – Letter of Intent (LOI) due. Please forward a copy of your LOI to Research Services.
- 30 September 2019 – invited applications submitted for internal review.
- Please email email@example.com if you are considering applying for this scheme.
- See also: Submitting an Application to Research Services for Review